Activated clotting time test alone is inadequate to optimize therapeutic heparin dosage adjustment during post-cardiopulmonary resuscitational extracorporeal membrane oxygenation (e-CPR)

Perfusion (United Kingdom)

Volumn 31, Issue 4, 2016, Pages 307-315

  Yie, Kilsoo ^a   Chon, Soon Ho Daniel ^a   Na, Chan Young ^b  

^a Cheju Halla General Hospital   (South Korea)

^b Keimyung University   (South Korea)

Author keywords

ACT; anticoagulation; aPTT; CPR; e CPR; ECMO; PCPS

Indexed keywords

HEPARIN;

ACTIVATED CLOTTING TIME TEST; ADULT; AGE; AGED; ARTICLE; BLEEDING; BLOOD CLOTTING PARAMETERS; BRAIN HEMORRHAGE; CONTROLLED STUDY; CORRELATIONAL STUDY; EXTRACORPOREAL OXYGENATION; FEMALE; HEMATOCRIT; HUMAN; INTERNATIONAL NORMALIZED RATIO; INTRAAORTIC BALLOON PUMP; LUNG HEMORRHAGE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; OROPHARYNGEAL HEMORRHAGE; PARTIAL THROMBOPLASTIN TIME TEST; PRIORITY JOURNAL; RESUSCITATION; SURVIVAL RATE; THROMBOCYTE COUNT; THROMBOEMBOLISM; TREATMENT DURATION; BLOOD CLOTTING TIME; CLINICAL TRIAL; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARDIOPULMONARY RESUSCITATION; EXTRACORPOREAL MEMBRANE OXYGENATION; FEMALE; HEPARIN; HUMANS; MALE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; WHOLE BLOOD COAGULATION TIME;

EID: 84971635760     PISSN: 02676591     EISSN: 1477111X     Source Type: Journal    
DOI: 10.1177/0267659115604710     Document Type: Article

References (32)

1. Chen YS, Lin JW, Yu HY, et al. Cardiopulmonary resuscitation with assisted extracorporeal life-support versus conventional cardiopulmonary resuscitation in adults with in-hospital cardiac arrest: an observational study and propensity analysis. Lancet 2008; 372: 554-561.
2. Levine MN, Hirsh J, Gent M, et al. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med 1994; 154: 49-56.
3. Hirsch J, Raschke R,. Heparin and low molecular weight heparin. The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004; 126: 188s-203s.
4. Smythe MA, Koerber JM, Nowak SN, et al. Correlation between activated clotting time and activated partial thromboplastin time. Ann Pharmacother 2002; 36: 7-11.
5. Nath FC, Muller DVM, Rosenschein U,. Heparin monitoring during coronary intervention: activated clotting time versus activated partial thromboplastin time. Can J Cardiol 1993; 9: 797-801.
6. Melandri G, Branzi A, Traini AM, et al. On the value of the activated clotting time for heparin monitoring in acute coronary syndromes. Am J Cardiol 1993; 71: 469-471.
7. Bowen FW, Edmunds HL Jr,. Coagulation, anticoagulation and the interaction of blood and artificial surfaces. In: Zwischenberger JB, Steinhorn RH, Bartlett RH, eds. ECMO: extracorporeal cardiopulmonary support in critical care. 3rd ed. Ann Arbor, ELSO; 2005. pp. 29-58.
8. Paden ML, Conrad SA, Rycus PT, Thiagarajan RR,. Extracorporeal Life Support Organization Registry Report 2012. ASAIO J 2013; 59: 202-210.
9. Rosborough TK,. Comparison of anti-factor Xa heparin activity and activated partial thromboplastin time in 2,773 plasma samples from unfractionated heparin-treated patients. Am J Clin Pathol 1997; 108: 662-668.
10. Adria C, Monchi M, Laurent I, et al. Coagulopathy after successful cardiopulmonary resuscitation following cardiac arrest. J Am Coll Cardiol 2005; 46: 21-28.
11. Oliver WCJ,. Overview of heparin and protamine management and dosing regimens in pediatric cardiac surgical patients. Semin Cardiothorac Vasc Anesth 2003; 7: 387-410.
12. Stub D, Bernard S, Pellegrino V, et al. Refractory cardiac arrest treated with mechanical CPR, hypothermia, ECMO and early reperfusion (the CHEER trial). Resuscitation 2015; 86: 88-94.
13. Atallah S, Liebl M, Fitousis K, Bostan F, Masud F,. Evaluation of the activated clotting time and activated partial thromboplastin time for the monitoring of heparin in adult extracorporeal membrane oxygenation patients. Perfusion 2014; 29: 456-461.
14. Baird CW, Zurakowski D, Robinson B, et al. Anticoagulation and pediatric extracorporeal membrane oxygenation: impact of activated clotting time and heparin dose on survival. Ann Thorac Surg 2007; 83: 912-919.
15. Despotis GJ, Joist JH, Hogue CW Jr, et al. More effective suppression of hemostatic system activation in patients undergoing cardiac surgery by heparin dosing based on heparin blood concentrations rather than ACT. Thromb Haemost 1996; 76: 902-908.
16. Rohrer MJ, Anta MN,. Effect of hypothermia on the coagulation cascade. Crit Care Med 1992; 20: 1402-1405.
17. Felfernig M, Blaicher A, Kettner SC, et al. Effects of temperature on partial thromboplastin time in heparinized plasma in vitro. Eur J Anaesthesiol 2001; 18: 467-470.
18. Gubler KD, Gentilello LM, Hassantash SA, et al. The impact of hypothermia on dilutional coagulopathy. J Trauma 1994; 36: 847-851.
19. Kettner SC, Kozek SA, Groetzner JP, et al. Effects of hypothermia on thrombelastography in patients undergoing cardiopulmonary bypass. Br J Anaesth 1998; 80: 313-317.
20. Reed RL 2nd, Johnson TD, Hudson JD, et al. The disparity between hypothermic coagulopathy and clotting studies. J Trauma 1992; 33: 465-470.
21. Fagnoul D, Taccone FS, Belhaj A, et al. Extracorporeal life support associated with hypothermia and normoxemia in refractory cardiac arrest. Resuscitation 2013; 84: 1519-1524.
22. Martini WZ, Cortez DS, Dubick MA, et al. Thromboelastography is better than PT, APTT and ACT in detecting clinically relevant clotting abnormalities after hypothermia, hemorrhagic shock and resuscitation in pigs. J Trauma 2008; 65: 535-543.
23. Wardrop D, Keeling D,. The story of the discovery of heparin and warfarin. Br J Haematol 2008; 141: 757-763.
24. Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists. Chest 2008; 133: 160S-198S.
25. Hyers TM, Hull RD, Weg JG,. Antithrombotic therapy for venous thromboembolic disease. Chest 1992; 102: 408S-425S
26. Pötzsch B, Madlener K, Seelig C, et al. The whole blood ecarin clotting time assay allows rapid and accurate monitoring of the anticoagulant response of r-hirudin during cardiopulmonary bypass. Thromb Hemost 1997; 77: 920-925.
27. Hafner G, Roser M, Nauck M,. Methods for the monitoring of direct thrombin inhibitors. Semin Thromb Hemost 2002; 28: 425-430.
28. Lidon RM, Theroux P, Juneau M, et al. Initial experience with a direct antithrombin, Hirulog, in unstable angina: anticoagulant, antithrombotic and clinical effects. Circulation 1993; 88: 1495-1501.
29. Swan SK, Hursting MJ,. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 2000; 20: 318-329.
30. Melloni C, Alexander KP, Chen AY, et al. Unfractionated heparin dosing and risk of major bleeding in non-ST segment elevation acute coronary syndromes. Am Heart J 2008; 156: 209-215.
31. Ranucci M, Ballotta A, Kandil H, et al. Bivalirudin-based versus conventional heparin anticoagulation for postcardiotomy extracorporeal membrane oxygenation. Crit Care 2011; 15: R275.
32. Kitchen S, Preston FE,. The therapeutic range for heparin therapy: relationship between six APTT reagents and two heparin assays. Thromb Haemost 1996; 75: 734-739.